When it comes to social media, Yahoo and Google have differing strategies but both work well.

Title: Leverage Facebook to Improve Brand Awareness and Promote Patient AdvocacyDate: Wednesday, March 24, 2010Time: 2:00 PM - 3:00 PM EDTRegister here: https://www1.gotomeeting.com/register/241889944Mention priority code P1606W1Twitter/BlogAbout the web seminar:In this web seminar, you’ll hear how McNeil Pediatrics created 2 successful Facebook communities ADHD MomsTM and ADHD AlliesTM, to

Did you know 92% of Americans get their breaking news from social media platforms, including mobile phones, Facebook pages and Twitter feeds?1 This May, find out how you can take advantage of these staggering statistics to drive real business results at IIR (and save $300 in the process if you register by THIS FRIDAY).Social Media & Community 2.0 Strategies Brochure DownloadRegister TodayWhat

I worked all weekend to submit to the FDA the results of the Pharma Marketing News/Blog survey of readers about FDA’s Regulation of Drug & Device Promotion via the Internet & Social Media. As you may recall, the FDA asked for comments relating to the following 5 issues: Issue 1: Accountability Issue 2: Fulfilling Regulatory Requirements Issue 3: Posting Corrective Information Issue 4: Links Issue 5: Adverse Event Reporting Under each issue, the FDA included several specific questions for which it was seeking answers. Beginning on September 21, 2009, Pharma Marketing News/Blog hosted an online survey/ questionnaire that included all 19 of these specific questions.

Bill Evans, SVP, Practice Group Lead, Fleishman Hillard Digital, aka @OhNoItsMBill on Twitter, just wrote a post entitled ” Why John Mack Needs His Head Examined .” At first, I thought it was a playful prank as sometimes happens among us pharma Twitterati. But then I noticed he was serious and called me “moronic” as in “his accusations are so moronic.” First, thanks to Bill for making this a personal vendetta against me. I really like the “moronic” remark

It’s official.

I like lists just about as much as I like statistics. That’s saying a lot. This week we saw the release of two new “lists” – The Top 500 Most Valuable Brands and the 25 Companies with the Best Customer Service

Yesterday, during a Pharma Marketing Talk live podcast/interview , Cynthia Phillips, who is currently Senior Director of Regulatory Labeling and Promotional Compliance at Millennium Pharmaceuticals, Inc., and spokesperson for an adhoc Social Media Working Group (SMWG), told how her group met with the FDA in October, 2009, and presented the agency with a draft guidance on regulating social media. This draft guidance may be similar to the comments SMWG submitted subsequently to the public docket (see ” A Pharma ‘Social Media Working Group’ Submits Comments to FDA “). Soon after its meeting with the SMWG, FDA held a public hearing on Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools

GSK continues to use its “More Than Medicine” blog to focus on Avandia, one of its medicines receiving a lot of attention recently (see Steve Nissen to GSK (and FDA): “Put Patients First! It’s Time to Pull Avandia from the Market.” ). In an early-evening post yesterday, blogger “Michael F”, complained of the “misleading headlines stating that ‘FDA Report Advises Avandia be Pulled from the Market,’” which he noted “were re-Tweeted dozens of times.” Then he pointed out that other commentary, which GSK found to be “more balanced” gained less attention. Michael F cited “this piece in Forbes,” as his example of a “more balanced” account (see here or screen shot below in case they delete or edit the post; click for enlarged view)

Internal FDA reports — part of a fierce debate within the agency over what to do about GSK’s Avandia — obtained by the New York Times , say that “if every diabetic now taking Avandia were instead given a similar pill named Actos, about 500 heart attacks and 300 cases of heart failure would be averted every month because Avandia can hurt the heart” (see ” FDA and GSK: Conflicting Opinions on Avandia Heart Dangers “).